scanX
Jubilant Pharmova
add_icon

Jubilant Pharmova

995.00
+3.25
(0.33%)
Market Cap
15,848.47 Cr
PE Ratio
39.73
Volume
1,49,716.00
Day High - Low
1,002.65 - 978.55
52W High-Low
1,248.00 - 786.05
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
15,848.47 Cr
EPS
25.15
PE Ratio
39.73
PB Ratio
2.23
Book Value
445.26
EBITDA
1,145.70
Dividend Yield
0.50 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
13.41
Debt to Equity
0.55
Analyst Rating and Forecast
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Jubilant Pharmova unit gets tax order8 days ago
Jubilant Generics received an Income Tax order for FY23 with adjustments of ₹107.89 crore. The subsidiary plans to appeal the order.
neutral
Jubilant Pharmova Eyes Margin Gains from H2 FY279 days ago
Jubilant Pharmova's Chairman expects EBITDA margins to improve from H2 FY27 as Montreal production stabilises, while CFO Arun Kumar Sharma resigns effective May 22, 2026.
neutral
Jubilant Pharmova re-appoints MDs for 3 years9 days ago
Jubilant Pharmova board approves re-appointment of Priyavrat Bhartia and Arjun Shanker Bhartia for three years from June 1, 2026, subject to shareholder approval.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,799.20
#1 4,31,688.35
38.46
#1 58,220.10
6.38
#1 11,565
25.80
46.23
Divis Laboratories
6,667.00
1,76,987.90
70.27
10,560.00
8.73
2,520
13.44
50.98
Torrent Pharmaceuticals
4,410.80
1,49,281.51
71.88
13,753.00
19.18
2,028
-26.91
52.33
Cipla
1,401.00
1,13,170.07
29.66
27,711.70
-2.46
3,783
-55.32
59.75
Dr Reddys Laboratories
1,303.50
1,08,795.72
26.48
33,593.30
-0.44
3,998
-86.05
50.35
Zydus Life Science
1,077.70
1,08,441.84
21.33
26,719.70
13.65
5,242
7.82
72.44
Lupin
2,267.70
1,03,643.69
#1 19.44
27,487.50
19.98
5,345
#1 87.72
45.61
Mankind Pharma
2,375.60
98,065.97
51.57
14,277.60
12.03
1,750
31.75
50.18
Aurobindo Pharma
1,426.40
82,845.54
23.80
33,384.70
3.21
3,376
1.99
45.43
Laurus Labs
1,362.00
73,528.47
83.76
6,812.90
#1 21.03
884
21.18
73.71
Growth Rate
Revenue Growth
12.81 %
Net Income Growth
-45.79 %
Cash Flow Change
10.38 %
ROE
900.75 %
ROCE
151.75 %
EBITDA Margin (Avg.)
-18.13 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Revenue
1,529
1,430
1,439
1,327
1,466
1,405
1,365
1,444
1,576
1,545
1,628
2,045
2,247
2,056
2,249
2,382
2,346
2,163
2,249
1,544
1,563
1,175
1,631
1,838
1,614
1,617
1,638
1,304
1,513
1,452
1,598
1,543
1,682
1,575
1,686
1,714
1,764
2,130
1,764
1,823
1,928
1,891
1,968
2,137
2,296
Expenses
1,323
1,121
1,129
1,061
1,192
1,051
1,045
1,126
1,293
1,219
1,336
1,651
1,794
1,663
1,828
1,899
2,262
1,747
1,798
1,141
1,131
977
1,242
1,293
1,216
1,269
1,319
1,116
1,280
1,259
1,440
1,408
1,459
1,419
1,439
1,459
1,656
1,480
1,477
1,554
1,587
1,611
1,631
1,873
1,964
EBITDA
206
309
310
266
274
354
319
318
283
327
293
394
453
393
422
483
83
415
451
403
432
199
389
546
398
348
319
187
233
192
158
134
223
156
247
255
108
650
287
269
341
280
337
264
332
Operating Profit %
13 %
21 %
21 %
20 %
19 %
25 %
23 %
22 %
17 %
21 %
18 %
19 %
19 %
19 %
19 %
19 %
4 %
19 %
20 %
24 %
24 %
13 %
20 %
26 %
22 %
21 %
19 %
14 %
15 %
13 %
9 %
8 %
12 %
9 %
14 %
12 %
5 %
14 %
15 %
14 %
17 %
14 %
17 %
12 %
14 %
Depreciation
66
70
75
75
127
72
72
73
75
73
79
82
182
88
90
98
95
103
117
84
98
82
85
96
86
88
100
93
101
95
94
94
271
90
97
95
101
91
91
91
95
98
105
121
117
Interest
85
91
92
89
99
83
80
98
80
69
66
77
73
51
54
53
62
73
72
49
47
48
47
46
43
35
35
37
40
40
42
51
56
62
66
71
73
71
61
56
53
49
50
56
57
Profit Before Tax
68
168
161
145
69
218
193
166
160
203
168
261
227
286
302
356
-40
269
292
294
358
106
299
431
297
247
208
70
106
69
36
9
-86
25
98
101
-54
500
144
131
206
154
190
93
176
Tax
25
37
36
24
58
54
50
48
11
60
43
48
74
86
92
88
61
84
43
90
98
18
75
121
83
86
65
19
47
22
32
25
14
19
36
35
8
18
42
30
55
52
70
38
57
Net Profit
43
130
125
122
11
164
144
118
149
144
126
213
152
200
210
268
-101
185
249
203
261
88
224
310
214
161
143
51
59
47
5
-16
-101
6
62
66
-62
482
103
101
151
103
120
56
119
EPS in ₹
2.68
8.28
8.11
7.90
0.72
10.39
9.29
7.66
9.63
9.44
8.23
13.64
9.94
13.00
13.50
16.74
-6.38
11.61
15.66
12.77
16.35
5.53
14.06
19.46
13.43
10.09
8.97
3.20
3.74
2.96
0.34
-0.98
-6.15
0.40
3.94
4.22
-3.69
30.44
6.47
6.37
9.71
6.49
7.59
3.52
7.55
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
12,756
15,523
Fixed Assets
4,911
5,104
5,107
5,401
5,648
6,340
4,609
4,871
5,183
5,091
5,176
8,180
Current Assets
2,715
2,875
2,948
3,190
4,585
5,038
2,953
3,509
3,762
3,876
3,577
4,109
Capital Work in Progress
597
611
684
671
901
768
897
1,090
1,562
2,103
3,630
2,962
Investments
0
85
103
124
115
69
241
239
256
42
44
1,232
Other Assets
3,111
3,023
3,147
3,423
4,804
5,344
3,171
3,792
4,156
4,312
3,907
0
Total Equity & Liabilities
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
12,756
15,523
Current Liabilities
2,129
2,464
1,684
2,005
2,090
2,619
1,049
1,592
1,772
1,889
2,165
2,539
Non Current Liabilities
4,036
3,432
3,968
3,578
4,570
4,299
3,128
3,083
3,993
4,238
4,353
5,888
Total Equity
2,454
2,928
3,389
4,035
4,809
5,604
4,742
5,316
5,392
5,421
6,239
7,093
Reserve & Surplus
2,438
2,951
3,421
4,071
4,793
5,588
4,726
5,303
5,383
5,418
6,239
7,077
Share Capital
16
16
16
16
16
16
16
16
16
16
16
16
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-82
-52
117
-212
761
225
-652
482
30
-58
132
Investing Activities
-362
-309
-465
-614
-1,018
-267
-727
-323
-474
-596
513
Operating Activities
783
1,099
1,269
1,303
1,122
1,543
1,784
838
661
971
1,072
Financing Activities
-503
-843
-686
-901
657
-1,050
-1,709
-33
-157
-433
-1,453
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Promoter
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
47.68 %
47.68 %
47.68 %
47.68 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
23.21 %
0.00 %
19.06 %
19.49 %
17.94 %
16.96 %
17.22 %
17.40 %
16.57 %
15.96 %
15.90 %
DIIs
0.78 %
1.15 %
0.40 %
0.43 %
0.05 %
0.04 %
0.39 %
1.62 %
0.40 %
1.63 %
1.65 %
1.50 %
3.78 %
4.07 %
5.66 %
6.98 %
7.05 %
9.53 %
10.52 %
11.22 %
11.62 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.24 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.07 %
16.98 %
19.03 %
18.97 %
19.27 %
19.35 %
19.01 %
18.68 %
18.69 %
18.25 %
18.24 %
18.76 %
18.71 %
17.79 %
18.09 %
18.09 %
17.75 %
17.97 %
18.02 %
17.85 %
17.57 %
Others
32.47 %
31.19 %
29.89 %
29.92 %
30.00 %
29.93 %
29.92 %
29.02 %
28.98 %
29.44 %
6.22 %
29.06 %
7.77 %
7.97 %
7.63 %
7.30 %
7.31 %
7.42 %
7.22 %
7.29 %
7.23 %
No of Share Holders
0
61,942
87,493
1,13,776
1,09,420
1,08,063
1,09,410
1,05,632
97,935
93,375
89,376
86,588
92,264
81,992
89,456
1,02,442
96,526
99,673
93,336
90,133
86,347

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 3 3 4.5 5 5 5 5 5 5 0.00
Dividend Yield (%) 0.36 0.45 1.81 0.73 1.29 1.79 0.88 0.56 0.61 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
01 Feb 2021 CHANGE OF NAME Change Of Name
NA
 01 Feb 2021 886.60 886.60
06 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
 05 Aug 2021 843.05 657.45
12 Aug 2022 DIVIDEND Dividend
₹ 5.00 /share
 11 Aug 2022 397.10 353.35
10 Aug 2023 DIVIDEND Dividend
₹ 5.00 /share
 10 Aug 2023 362.90 404.75
02 Aug 2024 DIVIDEND Dividend
₹ 5.00 /share
 02 Aug 2024 703.90 866.20
30 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 30 Aug 2024 849.00 920.60
25 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 25 Oct 2024 1,228.25 1,108.05
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Jan 2025 937.70 954.95
16 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 16 May 2025 896.35 905.60
25 Jul 2025 DIVIDEND Dividend
₹ 5.00 /share
 25 Jul 2025 905.60 1,175.00
29 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 Jul 2025 1,210.30 1,174.20
29 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 29 Aug 2025 1,119.10 1,039.30
31 Oct 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Oct 2025 1,097.50 1,118.40
06 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Feb 2026 946.80 974.50
22 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 22 May 2026 946.30 1,011.65

Announcements

USFDA Inspection Update - Contract Manufacturing Facility At Montreal Canada1 day ago
Compliances-Reg.24(A)-Annual Secretarial Compliance3 days ago
Earnings Call Transcript3 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication8 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome8 days ago
Tax Demand Order Received By Companys Step Down Subsidiary8 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release9 days ago
Announcement under Regulation 30 (LODR)-Change in Management9 days ago
Announcement under Regulation 30 (LODR)-Change in Directorate9 days ago
Announcement under Regulation 30 (LODR)-Change in Management9 days ago
Record Date9 days ago
Corporate Action-Board approves Dividend9 days ago
Audited Financial Results For The Quarter And Year Ended March 31. 20269 days ago
Board Meeting Outcome for Outcome Of Meeting Held On May 22 20269 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 18, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 29, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 24, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 24, 2026
Board Meeting Intimation for Meeting Held On May 22 2026Apr 24, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 01, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 31, 2026
Submission Of Communication Sent To ShareholdersMar 30, 2026
Closure of Trading WindowMar 27, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 27, 2026
USFDA Communication Montreal CanadaFeb 13, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2026
Un-Audited Financial Results For Quarter And Nine Months Ended December 31 2025Feb 06, 2026
Board Meeting Outcome for Meeting Held On February 06 2026Feb 06, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 02, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 02, 2026
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025Jan 22, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2026
Report On Special Window For Re-Lodgement Of Transfer Requests Of Physical SharesJan 02, 2026
Order Received From The Income Tax DepartmentDec 31, 2025
Announcement under Regulation 30 (LODR)-AcquisitionDec 30, 2025
Closure of Trading WindowDec 29, 2025
Jubilant Generics Limited - Order Passed By The Assistant Commissioner Central GST Division RoorkeeDec 27, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- Receipt Of Adjudication Order_GSTDec 05, 2025
Report On Special Window For Re-Lodgement Of Transfer Requests Of Physical SharesDec 02, 2025
Appointment Of Mr. Daniel J. OConnor As CEO Of Jubilant Therapeutics Inc.Dec 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 28, 2025
Submission Of Communication Email Sent To Shareholders Whose Dividend(S) Remains Unpaid Pursuant To "Saksham Niveshak - 100 Days Campaign"Nov 08, 2025
USFDA Communication Montreal CanadaNov 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 31, 2025
Approval For Grant Of Stock Options/RsusOct 31, 2025
Un-Audited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025Oct 31, 2025
Board Meeting Outcome for Meeting Held On October 31 2025Oct 31, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
JioBlackRock Flexi Cap Fund Direct-Growth
0.00%
-17045
-0.05%
-0.28%
Zerodha Nifty MidSmallcap400 50:50 Index Fund Direct-Growth
0.20%
172
0.20%
0.20%
UTI Nifty500 Shariah Index Fund Direct-Growth
0.13%
117
0.01%
0.01%
DSP Nifty Smallcap 250 Index Fund Direct-Growth
0.38%
63
0.00%
0.02%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.04%
10
0.00%
0.00%
Navi Nifty MidSmallcap 400 Index Fund Direct-Growth
0.13%
6
0.01%
0.01%
DSP Nifty 500 Index Fund Direct-Growth
0.04%
4
0.00%
0.00%
JioBlackRock Nifty Smallcap 250 Index Fund Direct-Growth
0.38%
3
-0.01%
0.01%
Groww Nifty Total Market Index Fund Direct-Growth
0.04%
0
0.00%
0.00%
HDFC Pharma And Healthcare Fund Direct-Growth
1.36%
0
0.00%
0.05%
Angel One Nifty Total Market Index Fund Direct-Growth
0.04%
0
0.00%
0.00%
Axis Nifty 500 Index Fund Direct-Growth
0.04%
0
0.00%
0.00%
Bajaj Finserv ELSS Tax Saver Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bajaj Finserv Healthcare Fund Direct-Growth
1.00%
0
0.00%
0.05%
Bajaj Finserv Small Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Aggressive Hybrid Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.53%
0
0.00%
0.03%
Bandhan Business Cycle Fund Direct-Growth
0.00%
0
0.00%
-0.03%
Bandhan Focused Fund Direct-Growth
4.71%
0
0.00%
0.00%
Bandhan Healthcare Fund Direct-Growth
0.96%
0
0.06%
0.08%
Bandhan Innovation Fund Direct-Growth
1.01%
0
0.00%
-0.03%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.37%
0
0.00%
-0.02%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.04%
0
0.00%
0.00%
Bandhan Small Cap Fund Direct-Growth
1.20%
0
0.00%
0.17%
Edelweiss Nifty Smallcap 250 Index Fund Direct-Growth
0.38%
0
0.00%
-0.01%

Technical Indicators

RSI(14)
Neutral
59.12
ATR(14)
Less Volatile
29.64
STOCH(9,6)
Neutral
56.31
STOCH RSI(14)
Oversold
9.73
MACD(12,26)
Bearish
-4.60
ADX(14)
Weak Trend
21.97
UO(9)
Bearish
59.07
ROC(12)
Uptrend And Accelerating
0.70
WillR(14)
Neutral
-48.01
Bearish
4
Neutral
3
Bullish
2

About Jubilant Pharmova

Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and...more
Website
https://www.jubl.com
Chairperson NameShyam S Bhartia
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104